Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (51923)	2/1/2022 11:56:12 AM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 52153

There’s a lot of skepticism that anything will work in NASH, and MDGL didn’t help its case by withholding the fibrosis data from the NAFLD study. (Disclosure: No position.)

To: A.J. Mullen who wrote (51923)	2/1/2022 3:19:44 PM
From: Art Bechhoefer	Read Replies (1) \| Respond to of 52153

Madrigal will probably get FDA approval on its NASH drug before competitors like Viking Therapeutics, which has a similar drug that requires much lower dosage for similar effectiveness. However, the fact that the Viking drug dosage is about one-fifth the dosage required by Madrigal makes VKTX look more attractive at its current price, even if Madrigal wins FDA approval earlier than Viking. Note that both drugs are similar in the way they work. Art